No Data
No Data
RBC Capital Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $74
RBC Capital analyst Brian Abrahams maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $74.According to TipRanks data, the analyst has a success rate of 48.6% an
Should You Hold Gilead Sciences (GILD)?
Gilead Sciences (GILD) Receives a Hold From RBC Capital
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
A Tech Reckoning Is Coming, Financial Pro Says. It's Time to Play Defense.
The Bahnsen Group's chief investment officer recommends taking the moment to buy stocks with a history of paying dividends in defensive sectors.